Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

FDA Approves Aficamten for Obstructive HCM

L.A. McKeown

December 29, 2025

News Daily News

Rising HF Burden in the US Potentially Related to Changes in Cardiometabolic Factors

Yael L. Maxwell

December 02, 2025

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

Presentation THT 2025

Obesity, Insulin Resistance, and Cardiovascular Disease: The Link between Metabolism and Inflammation

Presenter: Carolyn Lam

February 11, 2025

News Conference News AHA 2024

Nasal Bumetanide Safe, Effective in Healthy Adults

Yael L. Maxwell

November 18, 2024

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Daily News

One in Six COAPT Patients Had Malnutrition: TEER Helped Regardless

Shelley Wood

June 12, 2023

News Conference News ESC Heart Failure 2023

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

Shelley Wood

May 25, 2023

News Conference News EuroPCR 2023

Renal Denervation: Exploring Its Potential Beyond Hypertension

Todd Neale

May 18, 2023

News Opinion CV Team Dispatch

February 2023 News Roundup

L.A. McKeown

February 15, 2023

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Shelley Wood

November 14, 2021

News Daily News HFSA 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Michael O'Riordan

September 15, 2021

News Daily News

Smoker’s Paradox Debunked: Post-STEMI Outcomes Worse in Cigarette Smokers

Michael O'Riordan

April 15, 2020

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Daily News

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Michael O'Riordan

October 18, 2016

News Daily News

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Michael O'Riordan

October 18, 2016

News Industry News

Heart Metabolics Announces Initiation Of Phase 2b Study Of Perhexiline For Hypertrophic Cardiomyopathy

August 31, 2016

Advertisement

FDA Approves Aficamten for Obstructive HCM

Rising HF Burden in the US Potentially Related to Changes in Cardiometabolic Factors

What’s Going to Be Hot at AHA 2025?

Obesity, Insulin Resistance, and Cardiovascular Disease: The Link between Metabolism and Inflammation

Nasal Bumetanide Safe, Effective in Healthy Adults

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

June 2024 Dispatch for the CV Team

One in Six COAPT Patients Had Malnutrition: TEER Helped Regardless

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

Renal Denervation: Exploring Its Potential Beyond Hypertension

February 2023 News Roundup

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Smoker’s Paradox Debunked: Post-STEMI Outcomes Worse in Cigarette Smokers

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Heart Metabolics Announces Initiation Of Phase 2b Study Of Perhexiline For Hypertrophic Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content